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Abstract. Recent studies have focused on the role of gaso‑
transmitters in cancer progression and prevention. Therefore, 
the current study was designed to explore the vasodilator 
activity of NO and H2S in the human mesenteric arteries of 
patients with colorectal cancer (CRC) via the activation of K+ 
channels. A total of two sets of experiments were established 
for the current investigation. Blood samples from patients with 
CRC were obtained to detect serum levels of endocan and 
malondialdehyde (MDA). The role of K+ channels in mediating 
the vasodilation of the human mesenteric artery in response 
to sodium nitroprusside (SNP) and sodium disulfide (Na2S) 
was assessed. The level of serum endocan was indicated to 
be decreased in patients with CRC compared with healthy 
individuals, while the level of serum MDA remained unal‑
tered between groups. The arterial rings pre‑contracted with 
norepinephrine were first relaxed by the cumulative addition 
of increasing concentrations of either SNP (30 nM‑30 µM) or 
(1‑6 mM). Maximal relaxation rates were then calculated at 
15 min intervals for 60 min. Pre‑incubation of arterial rings 
for 20 min with individual K+ channel blockers was indicated 
to significantly reduce SNP‑ and Na2S‑induced relaxation at 
different time points. Pre‑treatment of L‑nitro‑arginine methyl 
ester did not alter vasodilation that was induced by Na2S. 
Furthermore, vasodilation of the CRC mesenteric artery was not 
altered by the synergistic application of SNP and Na2S, while 
pre‑incubation of arterial rings with D,L‑propargylglycine 
significantly enhanced vasodilation induced by SNP. These 
results indicated that endothelial dysfunction and oxidative 
stress do not serve roles in the pathogenesis of CRC. The 
dilatory mechanisms of NO and H2S in mesenteric arteries 
of patients with CRC were K+ channel‑ and time‑dependent, 
and the activity of cystathionine γ‑lyase enzyme inhibited the 
ability of exogenous NO in vasodilation processes.
Introduction
Globally, colorectal cancer (CRC) is the third most frequently 
detected neoplasm and the second leading cause of cancer‑ 
associated mortality, with >1.8 million new CRC cases and 
881,000 deaths being reported globally in 2018, with ~1 death 
per 10 confirmed cases (1,2). While the incidence of CRC in 
Middle Eastern countries is low (3), there is a higher annual 
incidence rate of CRC in the Kurdistan region of Iraq with an 
estimated ~38‑61.7 cases/100,000 people from 2006 to 2014. 
CRC is the fourth most widespread cancer in males and 
females residing in this province, causing ~8.6% mortality of 
the total annual fatalities in this region (4). There is strong 
evidence that CRC is the most common type of adenocarci‑
noma in this region (5).
Commonly endogenous gasotransmitters that are used are 
NO, CO and H2S (6). These small molecules of gas, which have 
limited concentrations and particular functions, are endoge‑
nously and enzymatically generated (7). NO is produced from 
L‑arginine by NO synthase (8,9), while H2S is synthesized from 
L‑cysteine by both cystathionine β‑synthase and cystathionine 
γ‑lyase (CSE), or mercaptopyruvate sulfurtransferase (10,11). 
The aforementioned gaseous molecules modulate different 
biological pathways and functions such as SMC relaxation, 
at physiologically relevant concentrations (6) by opening a 
number of membrane ion channels (12). NO is an essential regu‑
lator of angiogenesis (13) and vasorelaxation via the activation 
of guanylate cyclase and the production of cyclic guanidine 
monophosphate (cGMP) (14). cGMP increases endothelial 
Ca+2 concentration and contributes to the opening of localized 
Ca+2‑dependent K+ channels (KCa) (15). In contrast, H2S exerts 
its effects on vasodilation (16) and angiogenesis (17) via the 
direct activation of KATP channels (18).
NO and H2S also act synergistically or antagonistically to 
stimulate their downstream pathways, ranging from biosyn‑
thesis to their signaling cascade within target cells (19). NO 
and H2S are mutually dependent on regulating vasodilation, 
angiogenesis (20) and endothelial homeostasis (21). The role 
of these gases in cancer remains unclear, as both exhibit tumor 
promotion and anti‑tumor properties (22). Furthermore, NO 
and H2S have been indicated to modulate a variety of cancer 
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cell functions, including proliferation, invasion, metastasis and 
tumor angiogenesis (23). Additionally, the enzymes responsible 
for NO and H2S production are upregulated in CRC cells and 
endogenously produce low‑to‑mid concentrations of H2S or 
NO to support cell proliferation, while exogenous delivery of 
H2S or NO suppresses the division of colon cancer cells (24).
Intra‑tumor blood vessels are vital for tumor growth, 
metastasis, cancer treatment (25) and the acquisition of 
differential reactivity by functional mature blood vessels in 
the tumor micro‑environment, representing an appropriate 
target for anti‑tumor therapeutic agents (26). Cancerous cells 
exhibit accelerated metabolism and, therefore, demand high 
reactive oxygen species (ROS) concentrations to maintain 
high proliferation rates (27). The high level of ROS damages 
and/or destroys cells by oxidizing proteins, lipids and nucleic 
acids (28). These observations clarify that oxidative stress 
and cancer are closely associated (29). Several researchers 
are investigating the consequences of ROS and endothelial 
dysfunction in cancer (30‑32). Based on literature reviews, to 
the best of our knowledge, no studies appear to have presented 
an association between oxidative stress, endothelial functions 
and vascular reactivity of NO and H2S in patients with CRC. 
Therefore, the current study aimed to assess endocan as an 
endothelial functional marker and malondialdehyde (MDA) as 
an oxidative stress marker in patients with CRC. Additionally, 
the present study investigated the probable mechanisms 
responsible for NO‑ and H2S‑induced vasodilation in the 
human mesenteric artery of patients with CRC. To elucidate 
these mechanisms, the possible roles of different K+ channels 
in the vasodilation response produced by NO and H2S were 
explored.
Materials and methods
Patients. The current study was a case‑control study. For 
the first experiment, patients were recruited at two hospitals 
in Erbil, Iraq: The Oncology Department of Rizgary and 
Nanakaly Hospitals. Venous blood samples were taken from 
44 patients (male, 24; female, 20) with different stages of CRC. 
Additionally, 40 healthy volunteers (male, 22; female, 18) of 
similar ages were recruited randomly in Erbil city as control 
samples. For the second experiment, colorectal tumour 
specimens were obtained from patients with CRC undergoing 
partial colectomy at Consultancy Medical City and Welfare 
private hospitals in Erbil. In both experiments, patients were 
recruited between August to November 2016 and patient's 
median age was 55 years old (ranged between 35‑70). Patients 
with underlying immunodeficiency disorder or immunodefi‑
ciency state and individuals who had other co‑morbid health 
problems which could introduce heterogeneity to the sample, 
such as additional acquired brain injury, arthritis, chronic 
obstructive pulmonary disease, asthma, diabetes mellitus, 
ankylosing spondylitis, connective tissue diseases and other 
inflammatory diseases were excluded.
The blood samples were obtained by phlebotomy under 
an aseptic technique. Blood was placed into a clot activator 
tube for serum separation. The sera were then separated under 
centrifugation at 448 x g for 5 min at 37˚C. Patients with an 
underlying immunodeficiency disorder or state of immunode‑
ficiency, and individuals who presented with other co‑morbid 
health problems which could introduce heterogeneity to 
the sample (including arthritis, asthma, diabetes mellitus, 
hypertension and other inflammatory diseases) were excluded.
Determination of endocan. The concentrat ion of 
endocan was determined using the Human ESM1 ELISA 
kit (cat. no. E‑EL‑H1557; Elabscience, Inc.) by the 
Sandwich‑ELISA method (33). The micro ELISA plate was 
pre‑coated with antibodies specific to endocan. Standards 
or samples were added to the suitable micro ELISA plate 
wells and combined with the endocan‑specific antibodies 
(Elabscience, Inc.). A biotinylated detection antibody, 
part of the aforementioned kit, specific for endocan and 
avidin‑horseradish peroxidase (HRP)‑conjugate and substrate 
were then added to each well. Only the wells that contained 
endocan, biotinylated detection antibodies and avidin‑HRP 
conjugate appeared blue in color and the reaction was stopped 
with a 1N H2SO4 solution and the color turned yellow. The 
absorbance was measured spectrophotometrically (ELISA 
reader; Biotek) at a wavelength of 450 nm.
Determination of serum MDA. MDA was determined 
according to the Ohkawa method (34). The procedure started 
by thiobarbituric acid (TBA) preparation, in which 0.66 g TBA 
was dissolved in 100 ml of 0.05 M of NaOH with simple heating 
at 45˚C. Trichloroacetic acetic acid (TCA) was then prepared 
by dissolving 17.5 g TCA in 100 ml of distilled water. TCA2 
was prepared by dissolving 70 g of TCA in 100 ml of distilled 
water. Finally, 150 ml of either control or CRC patient's serum 
was added, 1 ml of TCA1 was mixed for 2 min and placed in 
a boiling water bath for 15 min and 1 ml of TCA2 was added 
and incubated for 20 min at 37˚C. The solution was centri‑
fuged for 5 min at 448 x g. The supernatant was read (Unico 
SpectroQuest SQ2800 UV‑Visible Spectrophotometer; Unico) 
at 532 nm.
Myographical recording
Vessel collection and preparation. Human mesenteric arteries 
were collected during surgery from patients with CRC under‑
going partial colectomy. The arteries supplying blood to the 
tumors were dissected surgically and placed into beakers 
containing cold modified Krebs solution (Sigma‑Aldrich; 
Merck KGaA) (Fig. 1) and aerated with 95% O2 and 5% CO2. 
The excess tissue and fat were removed in the laboratory and 
the arteries were cut into rings (length, ~3‑4 mm).
Recording of isometric tension. The procedure by Furchgott 
and Zawadzki (35) with certain modifications in the Krebs 
solution's concentration was followed to study the vasodilator 
activity of the isolated mesenteric arteries. The arterial rings 
were propped by two stainless steel clamps. The first clamp 
was attached to a hook at the underside of the organ bath and 
the second was connected to the force transducer through 
a thread to record the isometric tension of the mesenteric 
arteries. Data were recorded using LabChart 7.1 data acqui‑
sition software (ADInstruments, Inc.). The propped arterial 
rings were immersed in modified Krebs solution (NaCl 
5.10 gm/l, NaHCO3 1.94 gm/l, MgSO4 0.686 gm/l, KCl 
2.24 gm/l, KH2PO4 0.15 gm/l, CaCl2 0.277 gm/l and C6H12O6 
2 gm/l) and contained in a 10 ml organ chamber. Krebs 
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solution was maintained at a pH 7.4 and was constantly 
aerated with 95% O2 5% CO2 at 37˚C (panLab; Harvard 
Apparatus).
The mesenteric arterial rings were tensed to a stable basal 
strain of 4 gm prior to being left to be equilibrated for 2 h. 
The Krebs solution was replaced at 15‑20 min intervals in 
the bath chamber until it reached stability. Experimental 
substances were added to the bath chambers, according to 
protocol. The arteries were incubated at 37˚C with channel 
blockers for 20 min prior to pre‑contraction with norepineph‑
rine (NE; 1 µM; Sigma‑Aldrich; Merck KGaA). Following 
this, relaxation occurred by bolus dose application of sodium 
nitroprusside (SNP; Sigma‑Aldrich; Merck KGaA) or sodium 
sulphide (Na2S; Hangzhou J&H Chemical Co.).
Experimental protocol. The arterial rings, which were 
pre‑contracted with NE, were first relaxed by the cumulative 
addition of either SNP (30 nM‑30 µM) or Na2S (1‑6 mM). 
Based on these initial experiments, the relative half‑inhibitory 
concentration (IC50) of SNP (2.3 µM) or Na2S (2.4 mM) was 
used to retest the ability to relax pre‑contracted rings in three 
separate sets of experiments. In the first experiment, when the 
NE‑induced contraction reached the uppermost value, SNP 
(2.3 µM) or Na2S (2.4 mM) was added and left for 60 min, and 
the maximal relaxation rate (%) was calculated four times at 
each 15 min interval (n=8). Following this, the role of K+ chan‑
nels in the progress of SNP and Na2S mediated relaxation were 
tested via incubation at 37˚C of the arterial rings for 20 min using 
tetraethylammonium (TEA; 1 mM), glibenclamide (GLIB; 
0.1 µM), barium chloride (BaCl2; 1 mM) and 4‑aminopyridine 
(4‑AP; 1 mM) (all supplied from Hangzhou J&H Chemical 
Co.). In the second experiment, the role of endogenous NO 
and H2S were tested by the pre‑incubation of arterial rings 
with endothelial NO and CSE antagonists, L‑nitro‑arginine 
methyl ester (L‑NAME; 3x10‑4 M) or D,L‑propargylglycine 
(PAG; 10 mM) (Sigma‑Aldrich; Merck KGaA), respectively 
for 20 min prior to applying SNP (n=8). Finally, to examine 
whether the combination of H2S and NO potentiates or inhibits 
vasorelaxation when the NE‑induced contraction reached the 
highest value, SNP and Na2S were added simultaneously and 
left for 60 min (n=8).
Statistical analysis. Comparisons between patients with CRC 
and healthy individuals were performed using a Mann‑Whitney 
test, and values were presented as median and quartiles. 
Statistical analysis of myographical data was performed using a 
two‑way ANOVA followed by Dunnett post‑hoc test. Maximum 
relaxation responses were calculated as a percentage of the 
contraction produced by NE and expressed as the mean ± stan‑
dard error of the mean. The tension created by NE was defined 
as 0% relaxation, and the baseline tension prior to the addition 
of NE was determined as 100% relaxation.
The graphs, calculations and statistical analyses were 
performed using GraphPad Prism software (version 6.0; 
GraphPad Software, Inc.). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Serum endocan and MDA concentrations. Serum endocan 
concentration was significantly lower in patients with CRC 
(67.56; 43.04‑94.28) compared with healthy individuals (88.68; 
59‑101.3; Fig. 2A). There were no significant differences 
in MDA concentration between patients with CRC (3.62; 
2.86‑4.96) and healthy individuals (3.78; 3.23‑4.24; Fig. 2B).
Measurement of IC50. SNP concentrations ranging from 
30 nM‑30 µM induced a relaxant effect on CRC mesenteric 
arteries following pre‑contraction with NE (1 µM) with an 
IC50 value of 2.42±0.16 µM (CI 95%, 1.18‑4.95 µM). The 
percentage of relaxation was 80.74±7.256%. Na2S at concentra‑
tions from 1‑6 mM had a relaxant effect on mesenteric arteries 
of CRC pre‑contracted with NE. The calculated IC50 value 
was 3.54±1.07 mM (CI 95%, 1.4‑5.68 mM) and the percentage 
of relaxation was 84.43±22.05%. The concentration‑response 
curve for the effect of SNP and Na2S against NE‑mediated 
contractions are presented in Fig. 3A and B, respectively.
The role of K+ channels in the NO‑induced relaxation. 
Pre‑incubation of mesenteric arteries with either GLIB 
(0.1 µM; n=6) or TEA (1 mM; n=6) exhibited a significant 
reduction of net SNP‑induced vasorelaxation in mesenteric 
Figure 1. Mesenteric artery feeding a colon tumor. 
Figure 2. Comparison between (A) endocan and (B) MDA level in patients 
with CRC and healthy controls. Endocan was significantly decreased in 
patients with CRC compared with the healthy control group, while there were 
no significant differences MDA levels between groups. *P<0.05 vs. control. 
MDA, malondialdehyde; CRC, colorectal cancer. 
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arteries at all‑time points (Fig. 4). In contrast, vasorelaxation 
reduction by BaCl2 (1 mM; n=6) and 4‑AP (1 mM; n=6) 
was significant for 15‑45 min; however, reduction was not 
significant at 60 min compared with the SNP treatment group.
The role of K+ channels in the H2S‑induced relaxation. The 
impairment of Na2S‑inducing relaxation in mesenteric arteries 
was significantly sustained at time points 30, 45 and 60 mins 
following 4‑AP incubation (n=6; Fig. 5). GLIB (n=6) and 
BaCl2 (n=6) reduced vasorelaxation responses produced by 
Na2S only at time point 30 min. In contrast, TEA failed to 
ameliorate the vasorelaxation response of Na2S.
Interaction effects of SNP and Na2S. The combination of SNP 
and Na2S did not significantly alter the relaxation responses 
at any time point compared with the relaxation induced by 
the application of SNP or Na2S alone (Fig. 6A). Additionally, 
pre‑incubation of the arterial rings with L‑NAME (n=6) did 
not significantly change the extent of Na2S‑induced relaxation 
at any time point compared with the NasS treatment group 
(Fig. 6B). However, treating the mesenteric arterial rings with 
PAG (n=6) significantly increased vasorelaxation induced by 
the SNP at all‑time points (Fig. 6C).
Discussion
The current study revealed that the endothelium cells of 
patients with CRC were functioning normally since the levels 
of serum endocan, which is an endothelial cell marker, were 
significantly decreased compared with the controls (36). In 
this regard (37‑39), the reduction of endocan may be associated 
with chemotherapy, VEGF receptor‑2 kinase inhibitor treat‑
ment or the downregulation of endocan expression, indicating 
that the expression of endocan is associated with the develop‑
ment and differentiation of CRC (36). Furthermore, it has been 
demonstrated that endocan is associated with colon tumor size, 
depth of invasion, lymph node metastasis, distant metastasis 
and Dukes' staging (40). In addition to endocan, there has been 
a growing interest in MDA as a marker of oxidative stress 
in the progression of cancer (41). The present investigation 
demonstrated that there were no changes in the serum MDA 
levels in patients with CRC compared with controls. This is 
in contrast to a previous study that reported a considerable 
elevation in serum MDA levels in patients with CRC (42). 
Subramanyam et al (43) reported that chemotherapeutics 
normalized oxidative stress in patients with CRC. Collectively, 
these results indicated that the arteries in patients with CRC 
were intact and that their endothelia were functioning properly.
Furthermore, the current study demonstrated that SNP 
markedly relaxed mesenteric arteries in patients with CRC. 
A previous study by (44) recorded 69% relaxation in the 
mesenteric arteries in experimental rats compared with the 
control group, while a relaxation of 103% was recorded in a 
study investigating human arm veins (45). To investigate the 
mechanism of SNP‑induced relaxation, the role of K+ channels 
was investigated in the mesenteric arteries of patients with CRC.
The results of the present study revealed that K+ chan‑
nels exhibited a significant role of SNP‑induced relaxation in 
Figure 5. Time‑dependent change of relaxation responses to Na2S in 
mesenteric arteries preincubated with 4‑AP (1 mM), BaCl2 (1 mM), GLIB 
(10 µM) and TEA (1 mM). TEA had no significant effect on Na2S‑induced 
time‑dependent arterial relaxation. Na2S‑induced vasorelaxation was 
significantly inhibited by 4‑AP, BaCl2 and GLIB pretreatment. *P<0.05 
and **P<0.01 vs. the Na2S treatment group. Na2S, sodium sulfide; 4‑AP, 
4‑aminopyridine; BaCl2, barium chloride; GLIB, glibenclamide; TEA, 
tetraethylammonium. 
Figure 4. Time‑dependent change of relaxation responses to SNP in mesen‑
teric arteries preincubated with GLIB (10 µM), TEA (1 mM), 4‑AP (1 mM) 
and BaCl2 (1 mM). SNP‑induced vasorelaxation was significantly inhib‑
ited by GLIB, TEA, 4‑AP and BaCl2 pretreatment. *P<0.05, **P<0.01 and 
***P<0.001 vs. the SNP treatment group. SNP, sodium nitroprusside; GLIB, 
glibenclamide; TEA, tetraethylammonium; 4‑AP, 4‑aminopyridine; BaCl2, 
barium chloride. 
Figure 3. Cumulative dose‑response curve for the vasorelaxant effects 
of (A) SNP (30 nM‑30 µM) and (B) Na2S (1‑6 mM) on norepinephrine 
(1 µM)‑induced contraction in the mesenteric arteries of patients with 
colorectal cancer. SNP, sodium nitroprusside; Na2S, sodium sulfide. 
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mesenteric arteries following pre‑treatment with TEA, GLIB, 
BaCl2 or 4‑AP. All of these significantly inhibited vasodilation. 
A previous study demonstrated that NO activated several K+ 
channels of the small muscle cells (SMCs) of mesenteric and 
cerebral arteries in rats and rabbits, including ATP‑sensitive 
K+ channels, and induced membrane hyperpolarization by 
lowering [Ca2+]i levels via the inhibition of Ca2+ influx or 
Ca2+ release from intracellular storage (46). Furthermore, NO 
hyperpolarized arterial SMCs via the activation of both KV 
and KCa channels on vascular SMCs (VSMCs) in the rat supe‑
rior mesenteric, coronary, cerebral and large arteries (47‑49) 
through a cGMP‑dependent mechanism, subsequently inhib‑
iting the depolarization of the evoked membrane and upsurge 
in [Ca2+]i (50). The data obtained are compatible with earlier 
findings, where it was observed that NO regulated VSMC KIR 
currents (51). In contrast, Hempelmann et al (52) reported that 
neither 4‑AP nor BaCl2 modulated NO‑induced relaxation in 
the rat basilar artery. This conclusion indicated that NO may 
exert vasodilation, possibly by opening different K+ channels. 
Consequently, it can be concluded that K+ channels serves a 
crucial role in the vasodilation mechanism of NO.
To the best of our knowledge, in terms of the influence of 
Na2S on arterial relaxation, the current study was the first to 
observe the potency of Na2S in relaxing the mesenteric arteries 
of patients with CRC. The present study demonstrated that 
this relaxation was dependent on the activation of KATP and KV 
channels. The importance of KATP channel activation has been 
observed in the mesenteric arteries of the human colon (53), 
rat arterial smooth muscle (54) and human mammary 
arteries (55). The latter mechanism occurred either through 
the hyperpolarization of SMC membranes, which may close 
voltage‑gated Ca2+ channels (56), or through channel protein 
sulfhydration (16). On the other hand (53), concluded that H2S 
relaxed pre‑contracted human mesenteric arterial rings in a 
concentration‑dependent assay. Similarly, H2S induced vaso‑
relaxation in rat aortas, which was diminished by KCNQ‑type 
KV channel blockage (57).
In contrast, it has previously been shown that KATP chan‑
nels do not mediate H2S‑induced relaxation in the guinea‑pig 
ileum or the trout urinary bladder (58). Previous studies 
have reported that KIR channels weakly participate in the 
relaxation of mesenteric arteries in patients CRC and that the 
mechanism of relaxation in rat aortas was mainly mediated by 
the stimulation of KIR channels and subsequent KIR‑dependent 
hyperpolarization from endothelium to the SMCs (59‑61).
However, H2S was demonstrated to activate BKCa (62), 
IKCa and SKCa channels in endothelial cells (16) and BKCa 
channels in SMCs of mesenteric arteries (62) and cerebral 
arterioles (63). The results of the present study reported that 
TEA did not alter the vasodilation of mesenteric arteries 
induced by Na2S, indicating that KCa may not be a consider‑
able factor for H2S‑induced vasorelaxation. Similar results 
were observed by Tang et al (64), who noted that different KCa 
channel blockers were ineffective in the vascular impact of 
H2S. Contrary to the current results, the maximum relaxation 
of VSMC in rat (16,54,59) and human mammary (55) arteries 
induced by sodium hydrogen sulfide was significantly attenu‑
ated by KCa channel blockers. Whereas both H2S and NO are 
vasorelaxant factors with dissimilar mechanisms of action 
when applied in combination (54), the results of the current 
study reported that the combination of SNP and Na2S donors 
did not significantly alter maximum relaxation compared 
with the administration of SNP or Na2S alone. The generation 
of a novel molecule (perhaps nitrosothiol) via the combina‑
tion of H2S and NO does not relax blood vessels in vitro or 
in vivo (65). Consequently, the formation of this unique 
molecule most likely signifies an approach to biological 
inactivation or possibly sequestration of released NO (66). 
In contrast, rat aortic relaxation was prolonged when the gas 
donors were combined (67). This synergistic action may be 
due to the production of S‑nitrosothiol (HSNO) and nitroxyl 
(HNO) as the result of a chemical reaction between H2S and 
nitrite (68), which releases NO and polysulfides, and relaxes 
VSMCs through soluble guanylyl cyclase activation (69).
Simultaneously, pre‑incubation of L‑NAME did not alter 
Na2S‑induced relaxation. Similar results have been reported 
by (70,71). These authors demonstrated that L‑NAME did not 
modify the Na2S‑induced relaxation in isolated porcine irides. 
This conclusion indicated that endogenous NO does not have 
an impact on the vasoactivity of the H2S donor. In contrast, 
pre‑incubation of the arterial rings of patients with CRC with 
PAG did increase the relaxation activity induced by the NO 
donor. The justification for this reaction is associated with the 
activity of endogenous H2S in inhibiting the action of NO. In a 
Figure 6. Combined effect of SNP and Na2S on the time‑dependent relaxation responses of the mesenteric arteries precontracted with norepinephrine. 
(A) Combination of SNP and Na2S did not significantly alter time‑dependent relaxation compared with SNP or Na2S alone. (B) L‑NAME (3x10‑4 M) did not 
have a significant effect on Na2S‑induced time‑dependent relaxation. (C) SNP‑induced relaxation was significantly increased by PAG (10 mM) pretreatment. 
***P<0.001 vs. the SNP treatment group. SNP, sodium nitroprusside; Na2S, sodium sulfide; L‑NAME, L‑nitro‑arginine methyl ester; PAG, D, L‑propargylglycine. 
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similar manner, SNP‑induced vasorelaxation in rat aortas and 
human internal mammary arteries was diminished by a low 
concentration of H2S through the suppression of NO action or 
inhibition of NO synthase (56,64).
In 2015, Kashfi et al (72) investigated the effect of a 
NO‑ and H2S‑releasing hybrid on the growth properties of 
various (HCT116 and NCM356) CRC cell lines. Additionally, 
in 2017, Oláh et al (24) explored the expression of NO‑ and 
H2S‑generating enzymes in primary CRC tissues and the 
HCT116 CRC cell line. A limitation of the current study is 
that only the vasodilatory activity of NO and H2S donors 
in the human mesenteric artery of patients with CRC was 
investigated. Therefore, future studies should focus on 
assessing the molecular signaling pathways in CRC tissues 
and cell lines to provide a more comprehensive model of the 
expression patterns of NO and H2S enzymes.
In conclusion, low endocan and normal MDA levels in 
patients with CRC revealed that endothelial dysfunction and 
oxidative stress were not involved in the pathogenesis of CRC. 
Furthermore, the mechanism of NO and H2S‑induced mesen‑
teric artery vasodilation was time‑ and K+ channel‑dependent, 
as NO dilates mesenteric arteries via the activation of KATP, KCa, 
KIR and KV channels, while the vasodilation activity of H2S is 
due to the modulation of KATP and KV channels. Additionally, 
NO and H2S interacted at the enzyme level and the activity of 
the CSE enzyme inhibited the ability of exogenous NO in the 
vasodilatation process.
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